These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 18988126)

  • 41. Product-related research: how research can contribute to successful life-cycle management.
    Sandner P; Ziegelbauer K
    Drug Discov Today; 2008 May; 13(9-10):457-63. PubMed ID: 18468564
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Cost reductions and their effects on drug research].
    Götte D
    Med Klin (Munich); 2005 Jun; 100(6):309-13. PubMed ID: 15968482
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Chapter 5. The internationalization of the Japanese pharmaceutical industry (1980-2010)].
    Yongue JS
    Yakushigaku Zasshi; 2014; 49(1):77-83. PubMed ID: 25272639
    [TBL] [Abstract][Full Text] [Related]  

  • 44. How should we support pharmaceutical innovation?
    Grootendorst P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):313-20. PubMed ID: 19670991
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reviving an R&D pipeline: a step change in the Phase II success rate.
    Wu SS; Fernando K; Allerton C; Jansen KU; Vincent MS; Dolsten M
    Drug Discov Today; 2021 Feb; 26(2):308-314. PubMed ID: 33129994
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Financial returns on R&D: looking back at history, looking forward to adaptive licensing.
    Scannell JW; Hinds S; Evans R
    Rev Recent Clin Trials; 2015; 10(1):28-43. PubMed ID: 25925881
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The productivity crisis in pharmaceutical R&D.
    Pammolli F; Magazzini L; Riccaboni M
    Nat Rev Drug Discov; 2011 Jun; 10(6):428-38. PubMed ID: 21629293
    [TBL] [Abstract][Full Text] [Related]  

  • 48. R&D productivity rides again?
    Lendrem D; Senn SJ; Lendrem BC; Isaacs JD
    Pharm Stat; 2015; 14(1):1-3. PubMed ID: 25336017
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Future challenges and prospects for drug companies].
    Lajoux C
    Bull Acad Natl Med; 2008 Apr; 192(4):623-30; discussion 630-2. PubMed ID: 19024935
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development.
    Peck RW
    Drug Discov Today; 2007 Apr; 12(7-8):289-94. PubMed ID: 17395088
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Entering the contract research industry in India.
    Joseph J
    Contemp Clin Trials; 2008 May; 29(3):311-3. PubMed ID: 18053773
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An audience with...Marc Cluzel.
    Cluzel M
    Nat Rev Drug Discov; 2010 Jan; 9(1):14. PubMed ID: 20043024
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Today's biotech industry in India.
    Suresh N
    Biotechnol J; 2009 Mar; 4(3):291-4. PubMed ID: 19296434
    [No Abstract]   [Full Text] [Related]  

  • 54. Market watch: Trends in pharmaceutical company R&D spending: 2005-2015.
    Dixit R; David FS
    Nat Rev Drug Discov; 2017 Jun; 16(6):376. PubMed ID: 28496145
    [No Abstract]   [Full Text] [Related]  

  • 55. [Pharmaceutical industry and "New German Medicine" ("Neue Deutsche Heilkunde")].
    Meyer U
    Med Ges Gesch; 2004; 23():165-82. PubMed ID: 16025629
    [TBL] [Abstract][Full Text] [Related]  

  • 56. R&D efficiency of leading pharmaceutical companies - A 20-year analysis.
    Schuhmacher A; Wilisch L; Kuss M; Kandelbauer A; Hinder M; Gassmann O
    Drug Discov Today; 2021 Aug; 26(8):1784-1789. PubMed ID: 34022459
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multiscale mechanistic modeling in pharmaceutical research and development.
    Kuepfer L; Lippert J; Eissing T
    Adv Exp Med Biol; 2012; 736():543-61. PubMed ID: 22161351
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Where does novel antibiotics R&D stand among other pharmaceutical products: an industrial perspective?
    Tillotson GS
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):551-2. PubMed ID: 18847393
    [No Abstract]   [Full Text] [Related]  

  • 59. [Magic bullets, chemical gagging, controlled risks? On the research of the network "Pharmaceuticals in the 20th century" of the German Research Foundation (DFG)].
    Balz V; Bürgi M; Eschenbruch N; Hulverscheidt M
    Medizinhist J; 2008; 43(2):183-201. PubMed ID: 18839933
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Helping science to succeed: improving processes in R&D.
    Sewing A; Winchester T; Carnell P; Hampton D; Keighley W
    Drug Discov Today; 2008 Mar; 13(5-6):227-33. PubMed ID: 18342798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.